New antibody combo shows promise for tough childhood cancer

NCT ID NCT03363373

Ongoing Disease control Sponsor: Y-mAbs Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This phase 2 trial tests a combination of two drugs—naxitamab (an antibody) and GM-CSF (an immune booster)—in children and adults with high-risk neuroblastoma that has not responded well to previous treatments. The goal is to see if this therapy can shrink or eliminate tumors in the bone and bone marrow. Participants receive treatment for up to 101 weeks and are followed for five years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Naxitamab (a lab-made antibody) and GM-CSF (a protein that boosts immune cells)
What this could lead to: If successful, this could offer a new treatment option for patients with high-risk neuroblastoma that has not responded to standard therapy.
What could go wrong: This is a phase 2 trial with 122 participants, so results are still preliminary. The treatment may cause side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Milan, 20133, Italy
Giannina Gaslini Hospital

Genoa, Genoa, 16147, Italy
Hong Kong Children's Hospital

Hong Kong, Hong Kong
Hospital Infantil Universitario Niño Jesús

Madrid, 28009, Spain
Hospital Sant Joan de Déu

Barcelona, 08950, Spain
Hospital Universitario Virgen Del Rocío

Seville, Spain
Hospital Universitario y Politécnico La Fe

Valencia, 46026, Spain
Johannes Gutenberg-Universität

Mainz, Germany
Leeds General Infirmary

Leeds, LS1 3EX, United Kingdom
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Ospedale Pediatrico Bambino Gesù

Rome, Italy
Queen Mary Hospital

Hong Kong, Hong Kong
Rigshospitalet

Copenhagen, 2100, Denmark
Riley Hospital for Children

Indianapolis, Indiana, 46202, United States
Tata Memorial Centre

Mumbai, 400012, India
The Hospital for Sick Children

Toronto, M5G 1X8, Canada
The Royal Glasgow Children's Hospital

Glasgow, G51 4TF, United Kingdom
University Hospital Regensburg

Regensburg, Germany
University Hospital Southampton

Southampton, SO16 6YD, United Kingdom
University Medical Center Hamburg-Eppendorf

Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.